慢性肾病患者心肌梗死后从替格瑞洛降阶至氯吡格雷:随机临床试验的二次分析
该研究为TALOS-AMI随机临床试验的事后二次分析,纳入韩国32个心脏中心2014年2月至2018年12月入组的生物标志物阳性AMI且PCI后耐受1个月替格瑞洛为基础DAPT的患者,随机1:1继续替格瑞洛或换用氯吡格雷11个月。2646例中305例合并CKD(eGFR<60 mL/min/1.73 m2)。CKD患者缺血事件风险高于非CKD患者(HR 2.47,95%CI 1.38-4.42,P=.002),出血风险无差异(HR 1.36,95%CI 0.80-2.31,P=.26)。CKD患者中降阶组较继续替格瑞洛组主要终点风险降低(6.2% vs 13.1%;HR 0.45,95%CI 0.21-0.98,P=.04),BARC 2/3/5出血降低(2.5% vs 8.3%;HR 0.29,95%CI 0.09-0.89,P=.03),缺血事件无增加(4.4% vs 5.5%;HR 0.78,95%CI 0.28-2.16,P=.64)。作者认为需进一步足够把握度的研究验证。
要点
- CKD患者PCI后缺血事件风险高于非CKD患者(HR 2.47,95%CI 1.38-4.42,P=.002),出血风险无差异(HR 1.36,95%CI 0.80-2.31,P=.26)。
- CKD患者降阶至氯吡格雷较继续替格瑞洛主要终点降低(6.2% vs 13.1%;HR 0.45,95%CI 0.21-0.98,P=.04)。
- CKD患者降阶组BARC 2/3/5出血较继续替格瑞洛组降低(2.5% vs 8.3%;HR 0.29,95%CI 0.09-0.89,P=.03)。
- CKD患者降阶后缺血事件无增加(4.4% vs 5.5%;HR 0.78,95%CI 0.28-2.16,P=.64)。
- 作者认为需进一步足够把握度的研究验证上述发现。
适用人群与场景
- 生物标志物阳性AMI且PCI后耐受1个月替格瑞洛为基础DAPT的患者(TALOS-AMI试验纳入人群)。
- 本分析聚焦eGFR<60 mL/min/1.73 m2的CKD患者(305例,占11.5%;平均年龄67.2岁,男性73.1%,平均eGFR 49.7 mL/min/1.73 m2)。
诊断标准与关键阈值
- CKD定义:eGFR<60 mL/min/1.73 m2。
- 主要终点:心血管死亡、心肌梗死、卒中和出血(BARC 2、3或5型)的复合终点。
处置流程与药物剂量
- TALOS-AMI方案:PCI后1个月随机1:1继续替格瑞洛(活性对照组)或换用氯吡格雷(降阶组)治疗11个月。
研究设计与关键结果
- 研究类型:多中心、开放标签TALOS-AMI随机临床试验的事后二次分析,韩国32个心脏中心,2014年2月至2018年12月入组,随访至PCI后12个月。
- 总样本2646例,其中CKD 305例(11.5%),非CKD 2341例。
- CKD vs 非CKD:缺血事件HR 2.47(95%CI 1.38-4.42,P=.002);出血风险HR 1.36(95%CI 0.80-2.31,P=.26)。
- CKD患者降阶组(n=160)vs 活性对照组(n=145):主要终点10例(6.2%)vs 19例(13.1%),HR 0.45(95%CI 0.21-0.98,P=.04)。
- CKD患者降阶组 vs 活性对照组:BARC 2/3/5出血4例(2.5%)vs 12例(8.3%),HR 0.29(95%CI 0.09-0.89,P=.03)。
- CKD患者降阶组 vs 活性对照组:缺血事件7例(4.4%)vs 8例(5.5%),HR 0.78(95%CI 0.28-2.16,P=.64)。
证据类型、等级与局限
- 证据类型:随机临床试验的事后二次分析。
- 局限性:作者指出需进一步足够把握度的研究验证这些发现。
对床旁实践的改变
- 对于PCI后耐受1个月替格瑞洛为基础DAPT的合并CKD的AMI患者,降阶至氯吡格雷与主要终点和BARC 2/3/5出血风险降低相关,且缺血事件无增加;作者认为需进一步足够把握度的研究验证。
指南或共识出处
- TALOS-AMI随机临床试验(Ticagrelor vs Clopidogrel in Stabilized Patients With Acute Myocardial Infarction)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Chronic kidney disease (CKD) is a significant risk factor for both ischemic and bleeding complications following percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). Optimizing dual antiplatelet therapy (DAPT) is essential for improving clinical outcomes.
OBJECTIVE: To evaluate whether an 11-month, unguided deescalation strategy from ticagrelor to clopidogrel was associated with reduced bleeding without an increase in ischemic events in stabilized patients with CKD after AMI.
DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc secondary analysis of the multicenter, open-label, Ticagrelor vs Clopidogrel in Stabilized Patients With Acute Myocardial Infarction (TALOS-AMI) randomized clinical trial conducted at 32 major cardiac centers in South Korea. Patients with biomarker-positive AMI who tolerated 1 month of ticagrelor-based DAPT after PCI were included in the trial. Patient enrollment occurred from February 2014 to December 2018, with follow-up at 30 days and 3, 6, and 12 months after PCI. The present analysis focused on the subgroup of patients with CKD (estimated glomerular filtration rate [eGFR]<60 mL/min/1.73 m2). Data analyses were performed from July 2023 to October 2024.
INTERVENTIONS: In the TALOS-AMI trial, patients were randomized 1:1 to continue ticagrelor (active control group) or switch to clopidogrel (deescalation group) for 11 months after PCI.
MAIN OUTCOMES AND MEASURES: The primary end point was a composite of death from cardiovascular disease, myocardial infarction, stroke, and bleeding (Bleeding Academic Research Consortium [BARC] types 2, 3, or 5).
RESULTS: Of 2646 patients included in the trial, 305 had CKD (11.5%; mean [SD] age, 67.2 [11.4] years; 223 males [73.1%]; mean [SD] eGFR, 49.7 [9.5] mL/min/1.73 m2) and 2341 did not have CKD (1975 male [84.4%]; mean [SD] age, 59.0 [11.0] years). Patients with CKD had an increased risk of ischemic events compared with patients without CKD (hazard ratio [HR], 2.47; 95% CI, 1.38-4.42; P = .002), but there was no difference in bleeding risk (HR, 1.36; 95% CI, 0.80-2.31; P = .26). Among patients with CKD, deescalation (n = 160) vs active control (n = 145) was associated with reduced risks of the primary end point (10 patients [6.2%] vs 19 [13.1%]; HR, 0.45 [95% CI, 0.21-0.98]; P = .04) and BARC 2, 3, or 5 bleeding (4 patients [2.5%] vs 12 [8.3%]; HR, 0.29 [95% CI, 0.09-0.89]; P = .03). No increased risk of ischemic events was observed following deescalation (7 patients [4.4%] vs 8 [5.5%]; HR, 0.78 [95% CI, 0.28-2.16]; P = .64).
CONCLUSIONS AND RELEVANCE: In this secondary analysis of a randomized clinical trial, deescalation from ticagrelor to clopidogrel at 1 month after PCI for AMI was associated with significant reduction in bleeding without increased risk of ischemic events among study-eligible patients with CKD. Further adequately powered studies are needed to validate these findings.
参考来源
- Kim SH, Lee KY, Byeon J, et al. Deescalation From Ticagrelor to Clopidogrel for Myocardial Infarction With Chronic Kidney Disease: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2025. PMID: 40392554. doi:10.1001/jamanetworkopen.2025.11297
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。